The usefulness of a newly developed full-core biopsy needle in liver biopsy.

Abstract

To evaluate the usefulness and safety of a newly developed full-core biopsy needle. We selected 149 patients who underwent percutaneous liver biopsy at our institution from February 2019 to April 2021. We excluded 35 patients with hepatic fibrosis stage F3 or higher, which made it histopathologically difficult to measure the number of complete portal triads. The patients were divided into two groups as follows: 62 cases with the 18-G conventional automated needle (TruCore needle: T needle), and 52 cases with the 18-G full-core needle (CorVocet needle: C needle). We measured the number of complete portal triads in the liver tissue specimens, and the sum of the length and width of the collected tissues. Moreover, we compared the number of session counts, fragmentations, and complications. The sum of the length and the width was 12.8mm (11.2-14.3) and 15.9mm (13.1-17.3; p<0.001), and 0.68mm (0.63-0.74) and 0.82mm (0.78-0.90; p<0.001) for the T needle and C needle, respectively. The number of complete portal triads and fragmentation was six (3-8) and 10 (6-13; p<0.001), and one (1-10) and one (1-3; p<0.001), for the T needle and C needle, respectively. There was one session count (1-2) in both groups; however, there were significantly higher cases of two sessions with the T needle than that with the C needle (p=0.018). There were no serious adverse events. Compared with the conventional needles, the newly developed full-core needles enabled the acquisition of a larger amount of tissue sample in liver biopsy.